A novel prodrug‐based strategy to increase effects of bumetanide in epilepsy

Abstract

Our data demonstrate that the goal of designing bumetanide prodrugs that specifically target the brain is feasible and that such drugs may resolve the problems associated with using bumetanide for treatment of neurological disorders.